CriticalFirst-generation antipsychotic, butyrophenone. Used as antiemetic.×Atypical antipsychotic – indole derivative
Updated · Methodology
Mechanism
Both drugs prolong the QT interval: ziprasidone causes mild to moderate, dose-dependent prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In a study of 40 patients without known heart disease, droperidol prolonged QT in a dose-dependent way within 10 minutes of administration (droperidol label, US Food and Drug Administration, FDA). No studies have been done with ziprasidone and other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). Ziprasidone is an antipsychotic and droperidol a neuroleptic, and combining drugs that cause extrapyramidal symptoms can make these symptoms more frequent (droperidol SmPC, AEMPS). The documents describe no effect of either drug on the other's levels. Substances that inhibit CYP1A2 and CYP3A4 can slow droperidol metabolism (droperidol SmPC, AEMPS). According to the Spanish SmPC, ziprasidone is unlikely to change the metabolism of drugs handled by CYP3A4 to a clinically relevant degree (ziprasidone SmPC, AEMPS), and according to the US label it has little inhibitory effect on CYP1A2 (ziprasidone label, FDA).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With droperidol, QT prolongation, torsade de pointes, ventricular tachycardia and cardiac arrest have been reported, including in people with no known risk factors and at doses at or below those recommended. Some cases were fatal (droperidol label, US Food and Drug Administration, FDA). Bradycardia, low blood potassium or magnesium and other QT-prolonging drugs increase the risk of torsade de pointes and sudden death (ziprasidone label, FDA). Combining neuroleptics can make extrapyramidal symptoms such as dystonia, akathisia and oculogyric crisis more frequent (droperidol SmPC, AEMPS; droperidol label, FDA).
Management
The combination is contraindicated. The US ziprasidone label names droperidol among the drugs that ziprasidone should not be given with (ziprasidone label, US Food and Drug Administration, FDA). The Spanish droperidol summary of product characteristics (SmPC) contraindicates droperidol in patients treated with drugs known to prolong the QT interval (droperidol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and according to its own SmPC ziprasidone is one of them (ziprasidone SmPC, AEMPS). Droperidol is not on the list in the Spanish ziprasidone SmPC, but the SmPC states that ziprasidone should not be given with QT-prolonging drugs (ziprasidone SmPC, AEMPS). Do not give droperidol to a patient taking ziprasidone, including for the prevention and treatment of postoperative nausea and vomiting (droperidol SmPC, AEMPS). Before droperidol, record a 12-lead electrocardiogram (ECG) in all patients. Do not give droperidol if the corrected QT interval (QTc) is prolonged, that is, above 440 ms in men or 450 ms in women (droperidol label, FDA). In patients at risk of arrhythmia, check electrolytes and serum creatinine and exclude QT prolongation before droperidol. In patients with suspected ventricular arrhythmia or a known risk of it, monitor oxygen saturation continuously, including for 30 minutes after intravenous administration (droperidol SmPC, AEMPS). Avoid combining neuroleptics because of the risk of extrapyramidal symptoms (droperidol SmPC, AEMPS). Correct low potassium and magnesium before starting ziprasidone. If QTc exceeds 500 ms, the SmPC recommends interrupting treatment (ziprasidone SmPC, AEMPS). No document gives an interval between stopping ziprasidone and giving droperidol. The mean terminal half-life of oral ziprasidone is 6.6 hours (ziprasidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Inapsine (droperidol) prescribing information (2007)– FDA Inapsine label, boxed warning QT
- AEMPS: Ficha técnica: Zeldox (ziprasidona) (nº registro 64851), secciones 4.3 y 4.4 (2025)– AEMPS, CIMA, nº registro 64851, revisión 06/2025, secciones 4.3, 4.4 y 4.5
- FDA: Geodon (ziprasidone) prescribing information (2025)– FDA, DailyMed, setid a2b4cc65-6a6d-49c4-adfc-a4458562a167, Viatris Specialty, Revised 1/2025, sections 4.1, 5.3, 7.3
- AEMPS: Ficha técnica: Droperidol (nº registro 69837), sección 4.5 (2023)– AEMPS, CIMA, nº registro 69837 (Xomolix 2,5 mg/ml solución inyectable, Substipharm), revisión 08/2023, secciones 4.2, 4.3, 4.4, 4.5 y 4.8